SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC NEOPLASM
Clinical trials for SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC NEOPLASM trials appear
Sign up with your email to follow new studies for SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for mastocytosis patients: expanded access to bezuclastinib
Disease control AVAILABLEThis program provides the investigational drug bezuclastinib to adults with systemic mastocytosis who have failed or cannot tolerate standard treatments. Participants must be at least 18 years old and able to swallow tablets. The goal is to offer a potential treatment option when…
Matched conditions: SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC NEOPLASM
Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to tackle tough blood cancer
Disease control Recruiting nowThis early-phase study tests a combination of two drugs, avapritinib and decitabine, for people with a rare blood cancer called systemic mastocytosis with an associated hematologic neoplasm (SM-AHN). The goal is to find a safe dose that can control both parts of the disease. Abou…
Matched conditions: SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC NEOPLASM
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC